‘Competitors eye Eylea due to its many benefits’
By Jung, Sae-Im | translator Kim, Jung-Ju
23.08.08 06:18:17
가나다라
0
[Interview] Sangok Suh, Specialty Medicine BU Head, Bayer Korea
Leading macular degeneration treatment for the past decade... posted KRW 80 bil in sales last year
Will be competing with new drugs and biosimilars in the future...’Eylea’s solid strengths remain unwaivered’
The fact that many companies are concentrating on the development of Eylea biosimilars is proof of the many advantages owned by Eylea. We plan to continue to make known the strengths of Eylea while developing new products to continue to deliver on our patient and HCP-centric treatment strategy.”
Sangok Suh, Head of the Specialty Medicine business unit at Bayer Korea said so regarding Eylea’s off-patent strategy during an interview with DailyPharm.
▲Sangok Suh, Specialty Medicine BU Head, Bayer Korea
The anti-VEGF inhibitor Eylea is regarded as the long-standing powerhouse in the field of macular degeneration. The drug has been solidifying its lead in the market ever since it was approved in Korea in 2013. According to the market r
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)